These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2167352)

  • 21. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic immunization against herpes simplex virus. Protection is mediated by CD4+ T lymphocytes.
    Manickan E; Rouse RJ; Yu Z; Wire WS; Rouse BT
    J Immunol; 1995 Jul; 155(1):259-65. PubMed ID: 7602102
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monoclonal antibodies to the distinct antigenic sites on glycoproteins C and B and their protective abilities in herpes simplex virus infection.
    Bystrická M; Petríková M; Zatovicová M; Soláriková L; Kostolanský F; Mucha V; Russ G
    Acta Virol; 1997 Feb; 41(1):5-12. PubMed ID: 9199708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1.
    Wang K; Tomaras GD; Jegaskanda S; Moody MA; Liao HX; Goodman KN; Berman PW; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Kaewkungwal J; Haynes BF; Cohen JI
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28701403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune responses in mice induced by HSV-1 glycoproteins presented with ISCOMs or NISV delivery systems.
    Hassan Y; Brewer JM; Alexander J; Jennings R
    Vaccine; 1996 Dec; 14(17-18):1581-9. PubMed ID: 9032885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Virus neutralizing activity induced by synthetic peptides of glycoprotein D of herpes simplex virus type 1, selected by their reactivity with hyperimmune sera from mice.
    Geerligs HJ; Kocken CH; Drijfhout JW; Weijer WJ; Bloemhoff W; Wilterdink JB; Welling GW; Welling-Wester S
    J Gen Virol; 1990 Aug; 71 ( Pt 8)():1767-74. PubMed ID: 2167930
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protective immunity against herpes simplex virus (HSV) type 1 following oral administration of recombinant Salmonella typhimurium vaccine strains expressing HSV antigens.
    Karem KL; Bowen J; Kuklin N; Rouse BT
    J Gen Virol; 1997 Feb; 78 ( Pt 2)():427-34. PubMed ID: 9018066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The importance of MHC-I and MHC-II responses in vaccine efficacy against lethal herpes simplex virus type 1 challenge.
    Ghiasi H; Roopenian DC; Slanina S; Cai S; Nesburn AB; Wechsler SL
    Immunology; 1997 Jul; 91(3):430-5. PubMed ID: 9301533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of neutralizing antibody against varicella-zoster virus (VZV) by VZV gp3 and cross-reactivity between VZV gp3 and herpes simplex viruses gB.
    Kitamura K; Namazue J; Campo-Vera H; Ogino T; Yamanishi K
    Virology; 1986 Feb; 149(1):74-82. PubMed ID: 2418583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human natural killer cell recognition of herpes simplex virus type 1 glycoproteins: specificity analysis with the use of monoclonal antibodies and antigenic variants.
    Bishop GA; Marlin SD; Schwartz SA; Glorioso JC
    J Immunol; 1984 Oct; 133(4):2206-14. PubMed ID: 6206157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity of herpes simplex virus glycoproteins gC and gB and their role in protective immunity.
    Glorioso J; Schröder CH; Kumel G; Szczesiul M; Levine M
    J Virol; 1984 Jun; 50(3):805-12. PubMed ID: 6328010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of the role of antibody-dependent cellular cytotoxic antibody activity in murine neonatal herpes simplex virus infection with antibodies to synthetic peptides of glycoprotein D and monoclonal antibodies to glycoprotein B.
    Kohl S; Strynadka NC; Hodges RS; Pereira L
    J Clin Invest; 1990 Jul; 86(1):273-8. PubMed ID: 2164044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of monoclonal antibodies to HSV-1 and HSV-2 for serological analysis of the viral glycoproteins.
    Pereira L
    Dev Biol Stand; 1982; 52():115-31. PubMed ID: 6299824
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protection of guinea pigs from primary and recurrent herpes simplex virus (HSV) type 2 cutaneous disease with vaccinia virus recombinants expressing HSV glycoprotein D.
    Wachsman M; Aurelian L; Smith CC; Lipinskas BR; Perkus ME; Paoletti E
    J Infect Dis; 1987 Jun; 155(6):1188-97. PubMed ID: 3033094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preparation and efficacy of an inactivated subunit vaccine (NFUIBHK) against type 2 Herpes simplex virus infection.
    Skinner GR; Williams DR; Buchan A; Whitney J; Harding M; Bodfish K
    Med Microbiol Immunol; 1978 Nov; 166(1-4):119-32. PubMed ID: 214676
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune responses to herpes simplex virus in guinea pigs (footpad model) and mice immunized with vaccinia virus recombinants containing herpes simplex virus glycoprotein D.
    Aurelian L; Smith CC; Wachsman M; Paoletti E
    Rev Infect Dis; 1991; 13 Suppl 11():S924-34. PubMed ID: 1664130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implications for herpes simplex virus vaccine strategies based on antibodies produced to herpes simplex virus type 1 glycoprotein gC immune evasion domains.
    Chang YJ; Jiang M; Lubinski JM; King RD; Friedman HM
    Vaccine; 2005 Sep; 23(38):4658-65. PubMed ID: 15936852
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human cytotoxic T cell clones directed against herpes simplex virus-infected cells. IV. Recognition and activation by cloned glycoproteins gB and gD.
    Zarling JM; Moran PA; Burke RL; Pachl C; Berman PW; Lasky LA
    J Immunol; 1986 Jun; 136(12):4669-73. PubMed ID: 2423598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunization of experimental animals with reconstituted glycoprotein mixtures of herpes simplex virus 1 and 2: protection against challenge with virulent virus.
    Meignier B; Jourdier TM; Norrild B; Pereira L; Roizman B
    J Infect Dis; 1987 May; 155(5):921-30. PubMed ID: 3031174
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of a zwitterionic detergent for the preparation of an influenza virus vaccine: 2. Immunogenicity of Empigen-treated virus in animals.
    Mukhlis FA; Crawford CR; Jennings R; Potter CW
    Vaccine; 1984 Sep; 2(3):199-203. PubMed ID: 6531962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.